Earnings Miss: WuXi AppTec Co., Ltd. Missed EPS By 6.0% And Analysts Are Revising Their Forecasts
Earnings Miss: WuXi AppTec Co., Ltd. Missed EPS By 6.0% And Analysts Are Revising Their Forecasts
The quarterly results for WuXi AppTec Co., Ltd. (SHSE:603259) were released last week, making it a good time to revisit its performance. It looks like the results were a bit of a negative overall. While revenues of CN¥10b were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 6.0% to hit CN¥0.79 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
无锡药明康德有限公司(SHSE: 603259)的季度业绩已于上周公布,现在是重新审视其业绩的好时机。总体而言,结果似乎有点负面。尽管100元人民币的收入与分析师的预测一致,但法定收益低于预期,比预期低6.0%,达到每股0.79元人民币。分析师通常会在每份收益报告中更新他们的预测,我们可以从他们的估计中判断他们对公司的看法是否发生了变化,或者是否有任何新的问题需要注意。因此,我们收集了最新的财报后预测,以了解估计对明年的预测。
Taking into account the latest results, the consensus forecast from WuXi AppTec's 24 analysts is for revenues of CN¥43.2b in 2025. This reflects a decent 12% improvement in revenue compared to the last 12 months. Per-share earnings are expected to shoot up 31% to CN¥3.67. Before this earnings report, the analysts had been forecasting revenues of CN¥43.3b and earnings per share (EPS) of CN¥3.70 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
考虑到最新业绩,药明康德的24位分析师的共识预测是,2025年的收入为432元人民币。这反映出与过去12个月相比,收入增长了12%。预计每股收益将飙升31%,至3.67元人民币。在本财报发布之前,分析师一直预测2025年收入为433元人民币,每股收益(EPS)为3.70元人民币。因此,很明显,尽管分析师已经更新了估计,但在最新业绩公布后,对该业务的预期没有重大变化。
There were no changes to revenue or earnings estimates or the price target of CN¥62.66, suggesting that the company has met expectations in its recent result. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values WuXi AppTec at CN¥96.12 per share, while the most bearish prices it at CN¥20.50. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.
收入或收益预期或62.66元人民币的目标股价没有变化,这表明该公司在最近的业绩中达到了预期。但是,这并不是我们可以从这些数据中得出的唯一结论,因为一些投资者在评估分析师目标股价时也喜欢考虑估计值的差异。目前,最看涨的分析师对无锡安普泰克的估值为每股96.12元人民币,而最看跌的分析师估值为20.50元人民币。如您所见,估计范围很广,最低估值不到最看涨估计值的一半,这表明对于分析师认为该业务的表现存在强烈的分歧。因此,根据共识目标股价做出决策可能不是一个好主意,毕竟共识目标价只是如此广泛的估计值的平均值。
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the WuXi AppTec's past performance and to peers in the same industry. It's pretty clear that there is an expectation that WuXi AppTec's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 9.7% growth on an annualised basis. This is compared to a historical growth rate of 25% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 13% annually. Factoring in the forecast slowdown in growth, it seems obvious that WuXi AppTec is also expected to grow slower than other industry participants.
这些估计很有趣,但是在查看预测与无锡AppTec过去的表现以及与同一行业的同行进行比较时,可以更粗略地描述一些细节。很明显,预计药明康德的收入增长将大幅放缓,预计到2025年底的收入按年计算将增长9.7%。相比之下,过去五年的历史增长率为25%。相比之下,该行业的其他公司(根据分析师的预测),后者的总体收入预计每年将增长13%。考虑到增长放缓的预测,很明显,药明康德的增长速度预计也将低于其他行业参与者。
The Bottom Line
底线
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that WuXi AppTec's revenue is expected to perform worse than the wider industry. The consensus price target held steady at CN¥62.66, with the latest estimates not enough to have an impact on their price targets.
要了解的最重要的一点是,市场情绪没有重大变化,分析师再次确认该业务的表现符合他们先前的每股收益预期。幸运的是,分析师还重申了他们的收入预期,表明收入符合预期。尽管我们的数据确实表明,预计无锡AppTec的收入表现将比整个行业差。共识目标股价稳定在62.66元人民币,最新估计不足以对其目标股价产生影响。
With that in mind, we wouldn't be too quick to come to a conclusion on WuXi AppTec. Long-term earnings power is much more important than next year's profits. We have forecasts for WuXi AppTec going out to 2026, and you can see them free on our platform here.
考虑到这一点,我们不会很快就无锡AppTec得出结论。长期盈利能力比明年的利润重要得多。我们对药明康德的预测将持续到2026年,你可以在我们的平台上免费查看。
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for WuXi AppTec that you should be aware of.
别忘了可能仍然存在风险。例如,我们已经确定了您应该注意的无锡AppTec的1个警告信号。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。